NCT04604067
Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.
At risk: Primary completion moved 2 years 6 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 15 versions: 13 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Jul 30, 2026 to Jan 30, 2029 Show 4 more changesShow less
- Eligibility criteria expanded, about 40 words
- Secondary endpoints: details revised at 3 of 6 entries
- Study description shortened, about 11 words
- Site details revised at 1 of 19 sites
- Notable Primary completion date: Oct 2025 to Jul 30, 2026v14
- Study Identification, Study Status, Oversight, IPDSharingv12
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 19 of 19 sites
- Minor Site details revised at 2 of 19 sitesv10
Show 7 earlier versionsHide 7 earlier versions
- Notable Eligibility criteria expanded, about 37 words
- Primary completion date: Mar 2026 to Oct 2025
- Notable Primary completion date: Mar 2025 to Mar 2026
- Eligibility criteria expanded, about 55 words
- Study sites: 17 to 19
- Study description shortened, about 13 words
- Minor Study sites: 14 to 17v6
- Minor Study sites: 12 to 14v5
- Minor Start date changed from estimate of Oct 2021 to Jun 25, 2021v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised at 12 of 12 sites
- Notable Start date: Dec 2020 to Oct 2021v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
Cohort A: MYD88 L265P and/or CD79A/B mutations at baseline Treatment: Acalabrutinib-R-CHOP for a total number of 6 cycles. Cohort B, C D: Without MYD88 L265P and CD79A/B mutations at baseline: Assignment of cohort B, C and D after 2 cycles of R-CHOP according to PET (Deauville score (DS)) and molecular response (MR) (\>2log10 reduction of ctDNA) results: Cohort B: DS 4 and No MR Treatment: 2 cycles of acalabrutinib-R-CHOP. After PET3/ctDNA3: patients with DS 1-3 and no MR OR DS4 with MR will receive 2 additional cycles of acalabrutinb-R-CHOP and 2 cycles of acalabrutinib single agent. Cohort C: DS 1-3 and MR Treatment: 2 additional cycles of R-CHOP (4x RCHOP in total) followed by 2 cycles of rituximab single agent. Cohort D: DS 4 and no MR OR DS 1-3 and MR Treatment: 4 additional cycles of RCHOP (6 cycles in total). Follow up: Patients off treatment will be followed for 5 years.
Drugs: Acalabrutinib
Sites
19 sites in 2 countries
Switzerland 16, Italy 3